Ametris - formerly ActiGraph

01/09/2026

We hope you'll join us on January 28th for the first Digital Health Monthly webinar of 2026: Introducing 6M95C, A Novel Digital Measure for Tracking Disease Progression in Duchenne Muscular Dystrophy.

Accurately measuring disease progression across the full spectrum of Duchenne muscular dystrophy (DMD) remains a major challenge, especially as the disease progresses to a non-ambulatory stage. In a new study published in Pediatric Neurology, researchers introduce 6M95C, a novel accelerometry-based digital measure designed to complement the regulatory-qualified SV95C by capturing functional capacity across all disease stages, including in non-ambulatory patients.

During the webinar, several of the study authors, including Jonathon Soslow, MD MSCI of Vanderbilt University Medical Center and Ametris scientists Rakesh Pilkar and Andrew Liu, will discuss the development, validation, and clinical implications of 6M95C in DMD research.

⤵️Register now using the link in the comments below.

Can’t attend live? Register today, and you’ll receive the on-demand recording directly to your inbox.

01/08/2026

📣 New Suite of Digital Functional Capacity Measures for Neuromuscular Disorder Research!

Traditional functional assessments in neuromuscular disorder (NMD) research are most often episodic, effort-dependent, and limited to ambulatory patients. This means early signals can be missed and insight lost as the disease progresses.

To address these gaps and advance NMD research, Ametris has launched a new suite of digital measures designed to assess real-world functional capacity across all stages of NMD, including both ambulatory and non-ambulatory patients.

🔹 6M95C – A novel, accelerometry-based measure capturing peak movement over six minutes to track skeletal muscle function in ambulatory and non-ambulatory patients
🔹 SV95C – An EMA-qualified digital measure reflecting real-world walking performance, with proven sensitivity to meaningful change in Duchenne muscular dystrophy (DMD) and relevance across multiple NMDs

Together, 6M95C and SV95C enable continuous, real-world functional assessment and earlier detection of change across the full course of the disease, supporting stronger evidence generation in NMD research.

👉 Read the full product announcement linked below to explore the science, validation, and applications for these digital measures.

01/05/2026

🎉 Happy New Year!

Here at Ametris, 2025 was a year defined by growth, collaboration, and impact. In a new year-end blog reflection, Jeremy Wyatt, our CEO, looks back on key milestones and progress, from expanding our platform capabilities and rebranding as Ametris, to advancing digital evidence in oncology, launching DECODE Obesity, and growing the ADDS scientific community. Together, these efforts reinforced the importance of collaboration and rigor in digital measure adoption and inform our continued focus in 2026 on evidence generation and supporting clinical research.


👉 Read the full blog post using the link below.

12/31/2025

🚨Today is the last day for ADDS 2026 advanced pricing!

Join experts across clinical research, digital health, and life sciences at the ADDS 2026 Annual Scientific Conference, February 23–25 in Atlanta, GA.

ADDS 2026 brings together cutting-edge research and real-world applications of digital health technology across key areas including physical activity and mobility, sleep and scratch, AI, regulatory science, methodology and study design, and pharma innovation.

The program also features expert-led panel discussions, a dedicated scientific poster session, and multiple opportunities to connect with peers and collaborators across industry and academia.

👉 Register today to secure advanced pricing before it ends! Registration link in the comments below ⬇️

12/19/2025

⏰ ADDS 2026 Advance Pricing Ends December 31st!

Join leaders and experts across clinical research, digital health, and life sciences at the ADDS 2026 annual scientific conference, taking place February 23–25 in Atlanta, GA.

This year’s program highlights leading research and real-world applications across key areas of digital health, including:

🔹 Physical Activity & Mobility
🔹 Sleep & Scratch
🔹 Artificial Intelligence
🔹 Regulatory Science
🔹 Methodology & Study Design
🔹 Pharma Innovation

Plus, ADDS attendees will engage in expert-led panel discussions, explore emerging research during a dedicated scientific poster session, and connect with peers through numerous built-in networking opportunities designed to spark collaboration and insight.

Secure your spot before advance pricing ends and save $100! Registration link in the comments below ⬇️

12/16/2025

As regulatory engagement around digital health evolves, new opportunities are emerging to accelerate adoption in clinical research. At ADDS 2026, we'll host a dedicated ⭐Regulatory Session⭐ bringing together experts from FDA, Critical Path Institute, Eli Lilly and Company, and Ametris to explore how collaboration, evidence generation, and early engagement are shaping the next phase of digital health adoption. Presentation topics include:

✔️ Emerging approaches to regulatory engagement for digital health technologies
✔️ Lessons learned from real-world regulatory interactions
✔️ Opportunities for collaboration to support scalable, fit-for-purpose digital endpoints
✔️ Practical considerations for advancing adoption across therapeutic areas

We hope you’ll join us at ADDS 2026, Feb. 23-25 in Atlanta!

To learn more about ADDS 2026 and view the full agenda, visit the link in the comments below👇

12/11/2025

🚀 New Collaboration Announcement: AstraZeneca Joins DECODE Obesity as a Founding Partner!

Ametris is thrilled to welcome AstraZeneca as a founding partner in DECODE Obesity, our cross-industry collaboration to accelerate the development of validated digital endpoints for obesity research. AstraZeneca joins other DECODE Obesity founding partners Eli Lilly and Company, F. Hoffmann-La Roche, and Novo Nordisk, to collaboratively advance evidence generation and regulatory alignment for more mature assessments of physical activity and functional health.

Nayyar Iqbal, VP Clinical Metabolism, BioPharmaceuticals R&D at AstraZeneca shares, “Obesity isn’t just about a number on the scale—it’s a multifaceted disease that affects how people move, function, and sleep, and how they feel day to day. At AstraZeneca, we believe durable weight loss is key in delivering cardiorenal benefit against the interconnected diseases caused by obesity. By bringing continuous, real‑world assessments into DECODE Obesity, we can better capture meaningful changes in physical activity and functional health and reflect the full impact of treatment in people’s lives.”

We’re proud to expand this collaboration and continue strengthening the science behind next-generation obesity clinical endpoints.

⬇️ Read the full announcement using the link in the comments below.

12/10/2025

📣 We’re pleased to announce the abstracts and presenters selected for the ADDS 2026 Scientific Poster Session! This session showcases new, unpublished research using DHTs and offers an opportunity for attendees and presenters to connect, explore emerging findings, and discuss how we can continue moving the field forward. Here’s a preview of the selected abstracts:

🔎 Rationale for Digital Health Technology Assessments in FUNCtion ALS, a Phase 1/2 trial of TRCN-1023, an Antisense Oligonucleotide Restoring UNC13A, in Adult People Living with Amyotrophic Lateral Sclerosis | Sanjay Chandriani, Trace Neuroscience
🔎 Targeting Naturalistic Movement with Adaptive Deep Brain Stimulation in Parkinson’s Disease: a Randomized Feasibility Trial | Daryl Lawrence, UCSF
🔎 Digital Measures for Clinical Trial Endpoints in Huntington’s Disease (MEND-HD): Study Design and Status Update | Meghan Bjalme-Evans, MS, Columbia University
🔎 Evaluating The Safety and Efficacy of Sublingual Cannabidiol in Patients with Knee Osteoarthritis: A Double-Blind, Placebo-Controlled Crossover Trial | John Stauffer, University of Florida
🔎 Real-World Wrist-Derived Digital Mobility Outcomes in People with Multiple Long- Term Conditions: Comparative Algorithms Assessment | Dimitrios Megaritis, PhD, Northumbria University

To see the full abstract list, updated agenda, speakers, venue information, and registration details, visit the event website using the link in the comments below.👇

12/08/2025

🌙 New Resource for Sleep Disorder Researchers!

Sleep disorders like narcolepsy, idiopathic hypersomnia, and insomnia disrupt more than nighttime rest, they also influence daily functioning and overall well-being. With the rise of wearable digital health technologies, researchers can now capture continuous, real-world insights into how patients sleep, move, and respond to treatment.

We’ve developed a comprehensive Digital Endpoints Guide for Sleep Disorders Research to help clinical teams leverage these advances.

What’s inside:

🔹 How wrist-worn wearable DHTs support patient-centric sleep disorder drug development
🔹 Novel digital endpoints that reveal previously inaccessible clinical insights
🔹 Opportunities to remotely assess sleep behavior, daytime activity, vital signs, and more in natural settings

Unlock the full guide and explore how digital measures can elevate your next study: https://hubs.la/Q03XhfBk0

This guide provides information on how wearables unlock previously inaccessible clinical insights in sleep patients with real-world data

12/02/2025

As digital health technologies become foundational to clinical research, the ability to select the right wearables and generate high-quality, reliable data has never been more critical. Join us at ADDS Atlanta 2026 for a dedicated ⭐Methodology Session⭐exploring practical considerations for implementing DHT in clinical research, including wearable device selection and configuration, endpoint development approaches, and platform innovations to enhance digital data quality and operational efficiency. Presentation topics include:

📍Evaluating Consistency Across Wearable Devices
📍Approaches for Developing Wearable-Derived Clinical Endpoints
📍Understanding Sensor Configurations for Activity and Behavior Measurement
📍Advances in Digital Data Platforms and Analytics

We hope you’ll join us at ADDS 2026, Feb. 23-25 in Atlanta!

🔗 To view the full ADDS 2026 agenda, visit the link in the comments below.

12/01/2025

We’re excited to share a new publication in Pediatric Neurology co-authored by Ametris science team members Christine Guo, Rakesh Pilkar, and Andrew Liu, that advances how clinicians and researchers assess disease progression in Duchenne muscular dystrophy (DMD). The study introduces the Six-Minute Activity 95th Centile (6M95C), a novel accelerometry-based metric designed to capture a participant’s highest level of movement within any six-minute window.

Why 6M95C Matters:
🔹 Differentiates between ambulatory and non-ambulatory individuals
🔹 Shows moderately strong correlation with quantitative muscle testing
🔹 Declines over time, modeling progression of skeletal myopathy
🔹 Offers a potential effort-independent, real-world outcome measure for both ambulatory and non-ambulatory patients

This work highlights the power of continuous, real-world monitoring to unlock more sensitive and inclusive measures of functional decline in DMD.

Read the full publication in the comments below ⤵️

Full author list: Nicholas Joy, Jonathan Soslow, MD, MSCI, W.Bryan Burnette, MD, Andrew Liu, PhD, Christine C. Guo, PhD, Rakesh Pilkar, PhD, James C. Slaughter, DrPH, Meng Xu, MS, Kimberly Crum, RN, Karry Su, Christopher Spurney, MD, Nazia Husain, MBBS, MPH, Katheryn Gambetta, MD, Brian D. Soriano, MD, Frank J. Raucci, Jr., MD, PhD, Kan Hor, MD, Larry W. Markham, MD, Jaclyn Tamaroff, MD, MSCI